ProfileGDS5678 / 1456436_x_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 100% 100% 100% 100% 100% 99% 99% 100% 100% 100% 100% 100% 99% 100% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 113.6996100
GSM967853U87-EV human glioblastoma xenograft - Control 213.7416100
GSM967854U87-EV human glioblastoma xenograft - Control 313.774100
GSM967855U87-EV human glioblastoma xenograft - Control 413.8867100
GSM967856U87-EV human glioblastoma xenograft - Control 513.7219100
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 113.507599
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 213.482299
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 313.7377100
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 413.7093100
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 113.6974100
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 213.6579100
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 313.8482100
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 413.585699
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 513.8262100